Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY PRODUCT
• Overview
• Comparison by product
• NADs
• Antibiotics
• Others
• Market opportunity by product

PART 10: MARKET SEGMENTATION BY DISEASE SEVERITY
• Overview
• CHE
• OHE

PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas
• EMEA
• APAC
• Key leading countries
• Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 15: MARKET TRENDS
• Technological advances
• Emergence of novel treatment targets

PART 16: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 17: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ASKA Pharmaceutical
• COSMO PHARMACEUTICALS
• Mallinckrodt
• Valeant

PART 18: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Interorgan ammonia metabolism in healthy liver
Exhibit 02: WHC classification of HE
Exhibit 03: Recommended treatment pathway for HE
Exhibit 04: Parent market
Exhibit 05: Global CNS disorders drugs market: Segments
Exhibit 06: Market characteristics
Exhibit 07: Global HE therapeutics market: Segments
Exhibit 08: Market definition: Inclusions and exclusions checklist
Exhibit 09: Market size 2017
Exhibit 10: Validation techniques employed for market sizing 2017
Exhibit 11: Global HE therapeutics market 2017-2022 ($ millions)
Exhibit 12: Global HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition: Five forces 2017
Exhibit 21: Pipeline landscape by development phase
Exhibit 22: Key clinical trials
Exhibit 23: Global HE therapeutics market: Segmentation by product 2017-2022 (%)
Exhibit 24: Comparison by product
Exhibit 25: Global NAD HE therapeutics market 2017-2022 ($ millions)
Exhibit 26: Global NAD HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 27: Global antibiotic HE therapeutics market 2017-2022 ($ millions)
Exhibit 28: Global antibiotic HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 29: Global other HE therapeutics market 2017-2022 ($ millions)
Exhibit 30: Global other HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 31: Market opportunity by product
Exhibit 32: Customer landscape
Exhibit 33: Global HE therapeutics market: Segmentation by geography 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: HE therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 36: HE therapeutics market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 37: HE therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 38: HE therapeutics market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 39: HE therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 40: HE therapeutics market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: ASKA Pharmaceutical: Overview
Exhibit 49: ASKA Pharmaceutical: Business segments
Exhibit 50: ASKA Pharmaceutical: Organizational developments
Exhibit 51: ASKA Pharmaceutical: Segment focus
Exhibit 52: ASKA Pharmaceutical: Key offerings
Exhibit 53: ASKA Pharmaceutical: Key customers
Exhibit 54: COSMO PHARMACEUTICALS: Overview
Exhibit 55: COSMO PHARMACEUTICALS: Business segments
Exhibit 56: COSMO PHARMACEUTICALS: Organizational developments
Exhibit 57: COSMO PHARMACEUTICALS: Segment focus
Exhibit 58: COSMO PHARMACEUTICALS: Key offerings
Exhibit 59: COSMO PHARMACEUTICALS: Key customers
Exhibit 60: Mallinckrodt: Overview
Exhibit 61: Mallinckrodt: Business segments
Exhibit 62: Mallinckrodt: Organizational developments
Exhibit 63: Mallinckrodt: Geographic focus
Exhibit 64: Mallinckrodt: Segment focus
Exhibit 65: Mallinckrodt: Key offerings
Exhibit 66: Mallinckrodt: Key customers
Exhibit 67: Valeant: Overview
Exhibit 68: Valeant: Business segments
Exhibit 69: Valeant: Organizational developments
Exhibit 70: Valeant: Geographic focus
Exhibit 71: Valeant: Segment focus
Exhibit 72: Valeant: Key offerings
Exhibit 73: Valeant: Key customers